Today's corporate updates show a blend of strategic advancements and financial performance across sectors. Wellnex Life reported a positive turnaround with an EBITDA profit, Jersey Electricity recommended a final dividend, and Air China released its November operating data. Key strategic developments include Aptamer Group's licensing agreement with Twist Bioscience and Fusion Antibodies' launch of its OptiMAL platform, alongside Walker Crips progressing its acquisition and Haydale Graphene completing an oversubscribed retail offer. Meanwhile, South32 will place its Mozal Aluminium smelter on care and maintenance due to an unresolved electricity supply agreement, while Capital Limited saw a significant insider share acquisition.
Wellnex Life WNX reported encouraging initial results from its turnaround strategy, achieving an EBITDA profit of $0.1m for November. This positive shift was attributed to increased gross profit and strict cost controls. Year-to-date, the company's EBITDA has shown a 69% improvement over the previous year, demonstrating progress in its core focus on scaling the Pain Away brand and expanding contract manufacturing. Management continues to deprioritise non-core activities to concentrate resources on margin improvement.
Jersey Electricity JEL released its annual financial report for the year ended 30 September 2025, with the Board approving the final accounts. Directors recommended a final dividend of 12.60p per ordinary share, reflecting the company's full-year performance. The financial information is derived from statutory accounts, which were unmodified by the auditor.
Air China disclosed its key operating data for November 2025, presenting combined performance figures for the company and its subsidiaries. This monthly update provides investors with vital statistics on the airline's operational activity, offering insights into recent passenger numbers, cargo volumes, and capacity utilisation. The announcement reflects the company's ongoing performance within the aviation sector.
South32 S32 will place its Mozal Aluminium smelter into care and maintenance from March 2026, after failing to secure a sufficient and affordable electricity supply agreement. Despite continuous engagement with the Government of Mozambique, Hidroeléctrica de Cahora Bassa, and Eskom, parties remained deadlocked on pricing, further complicated by drought conditions. Raw materials for post-March 2026 operations have not been procured, leading to this significant operational decision.
Walker Crips Group WCW announced the publication and posting of its Scheme Document in connection with the recommended cash acquisition by PhillipCapital UK. This crucial development advances the takeover process, providing shareholders with comprehensive details regarding the proposed acquisition. Shareholder meetings to approve the scheme of arrangement are scheduled for 15 January 2026.
Capital CAPD Limited reported a significant director dealing, with BPM Investments, a related party of Executive Chair Jamie Boyton, acquiring 124,374 Common Shares. This transaction, part of a placing, increases Mr. Boyton's total direct and indirect shareholding to 21,994,066 Common Shares, equating to 9.76% of the company's enlarged share capital. The substantial increase in insider ownership indicates strong confidence in the company's future prospects.
Aptamer Group APTA announced a non-exclusive licensing agreement with Twist Bioscience, a prominent synthetic biology company. The agreement permits Twist Bioscience to utilise Aptamer's proprietary enzyme-modulating Optimer binder in its next-generation sequencing (NGS) and hot-start PCR products. This strategic collaboration positions Aptamer to capitalize on the rapidly growing NGS market, estimated to reach US$23.6bn by 2029, by partnering with a key market leader in synthetic DNA.
Fusion Antibodies FAB announced the official launch of its OptiMAL Human Antibody Discovery platform, designed for identifying novel human antibodies. The platform integrates the company's unique naive, synthetic library of antibody sequences with Mammalian Display technology. This innovation, protected by a US patent and additional pending patents, aims to accelerate the discovery and development of human therapeutic antibodies for the market.
Haydale Graphene Industries HAYD announced the successful completion of its Retail Offer, raising £0.50 million through the issuance of 100,000,000 Retail Shares. The offer, priced at 0.5 pence per share, was significantly oversubscribed, reflecting strong investor demand. Allocations were made to existing shareholders, applying principles of soft pre-emption. This capital raise will support the company's ongoing operations and development in the graphene industry.